In conclusion, these results indicate that curcumin is capable of reducing the expression of VEGF, VEGFR and K-ras, which results in the repression of HCC tumor growth, invasion and metastasis, and that curcumin interacts with the same signaling pathway as bevacizumab. The gene discussed is KDR; the disease is hepatocellular carcinoma.